CONSIDER – Core Outcome Set in IAD Research: international and multidisciplinary consensus on a core set of outcome domains in incontinence-associated dermatitis research

Table S1. Characteristics of the panelists per round of the Delphi study

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Round 1** | | **Round 2** | **Round 3** |
|  | **Group 1**† | **Group 2**‡ |
| *n (%)* | n = 28 | n = 29 | n = 43 | n = 37 |
| **Country** |  |  |  |  |
| Australia | 3 (10.7) | 1 (3.4) | 3 (7) | 3 (8.1) |
| Austria | 2 (7.1) | 4 (13.8) | 5 (11.6) | 5 (13.5) |
| Belgium | 8 (28.6) | 4 (13.8) | 10 (23.3) | 6 (16.2) |
| Canada | 1 (3.6) | 0 (0.0) | 1 (2.3) | 1 (2.7) |
| Chile | 0 (0.0) | 1 (3.4) | 1 (2.3) | 1 (2.7) |
| Czech Republic | 0 (0.0) | 1 (3.4) | 1 (2.3) | 1 (2.7) |
| France | 0 (0.0) | 1 (3.4) | 1 (2.3) | 0 (0.0) |
| Italy | 1 (3.6) | 0 (0.0) | 1 (2.3) | 1 (2.7) |
| Germany | 0 (0.0) | 1 (3.4) | 1 (2.3) | 1 (2.7) |
| Norway | 0 (0.0) | 1 (3.4) | 1 (2.3) | 1 (2.7) |
| South Africa | 2 (7.1) | 0 (0.0) | 2 (4.7) | 2 (5.4) |
| Spain | 0 (0.0) | 1 (3.4) | 1 (2.3) | 1 (2.7) |
| Sweden | 1 (3.6) | 2 (6.9) | 2 (4.7) | 2 (5.4) |
| Thailand | 1 (3.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Turkey | 1 (3.6) | 0 (0.0) | 1 (2.3) | 1 (2.7) |
| United Kingdom | 5 (17.9) | 4 (13.8) | 6 (14.0) | 5 (13.5) |
| United States | 3 (10.7) | 8 (27.6) | 6 (14.0) | 6 (16.2) |
| **Gender** |  |  |  |  |
| Female | 21 (75) | 21 (72.4) | 31 (72.1) | 27 (73.0) |
| **Age** |  |  |  |  |
| mean (SD) years | 50.0 (8.7) | 50.7 (8.2) | 49.7 (8.8) | 49.6 (8.9) |
| **Education** |  |  |  |  |
| High school | 1 (3.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| College degree | 1 (3.6) | 1 (3.4) | 2 (4.7) | 2 (5.4) |
| Bachelor degree | 6 (21.4) | 2 (6.9) | 7 (16.3) | 5 (13.5) |
| Master degree | 9 (32.1) | 9 (31.0) | 10 (23.3) | 10 (27.0) |
| Doctoral degree | 11 (39.3) | 15 (51.7) | 23 (53.5) | 19 (51.4) |
| Other | 0 (0.0) | 2 (6.9) | 1 (2.3) | 1 (2.7) |
| **Current work setting** |  |  |  |  |
| Local hospital | 4 (14.3) | 2 (6.9) | 2 (4.7) | 1 (2.7) |
| Teaching / university hospital | 10 (35.7) | 13 (44.8) | 20 (46.5) | 18 (48.6) |
| Community care | 1 (3.6) | 0 (0.0) | 1 (2.3) | 1 (2.7) |
| Education | 5 (17.9) | 4 (13.8) | 6 (14.0) | 6 (16.2) |
| Clinical research | 1 (3.6) | 2 (6.9) | 3 (7.0) | 3 (8.1) |
| Industry / commercial | 5 (17.9) | 4 (13.8) | 7 (16.3) | 5 (13.5) |
| Other | 0 (0.0) | 2 (6.9) | 1 (2.3) | 1 (2.7) |
| Missing | 2 (7.1) | 0 (6.9) | 3 (7.0) | 2 (5.4) |
| **Role** § |  |  |  |  |
| Clinician (nurse) | 14 (50) | 15 (51.7) | 20 (46.5) | 18 (48.6) |
| Clinician (medical doctor) | 2 (7.1) | 2 (6.9) | 4 (9.3) | 2 (5.4) |
| Clinician (other) | 0 (0.0) | 2 (6.9) | 2 (4.7) | 1 (2.7) |
| Clinical researchers | 6 (21.4) | 9 (31) | 12 (27.9) | 13 (35.1) |
| Educator | 14 (50) | 18 (62.1) | 27 (62.8) | 26 (7.03 |
| Research and development | 12 (42.9) | 13 (44.8) | 20 (46.5) | 17 (45.9) |
| Industry | 3 (10.7) | 1 (3.4) | 4 (9.3) | 3 (8.1) |
| Other | 2 (7.1) | 2 (6.9) | 2 (4.7) | 2 (5.4) |
| **Field of work** § |  |  |  |  |
| General medicine | 2 (7.1) | 2 (6.9) | 2 (4.7) | 2 (5.4) |
| Nursing | 15 (53.6) | 21 (72.4) | 28 (65.1) | 27 (73.0) |
| Dermatology | 4 (14.3) | 6 (20.7) | 9 (20.9) | 5 (13.5) |
| Wound care | 17 (60.7) | 18 (62.1) | 26 (60.5) | 21 (56.8) |
| Psychology | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Geriatrics | 4 (14.3) | 4 (13.8) | 5 (11.6) | 5 (13.5) |
| Education | 9 (32.1) | 16 (55.2) | 21 (48.8) | 20 (54.1) |
| Methodology / statistics | 2 (7.1) | 2 (6.9) | 3 (7.0) | 2 (5.4) |
| Intensive care | 5 (17.9) | 5 (17.2) | 6 (14.0) | 6 (16.2) |
| Long-term care | 1 (3.6) | 4 (13.8) | 3 (7.0) | 3 (8.1) |
| Rehabilitation Care | 0 ( 0.0) | 2 (6.9) | 2 (4.7) | 1 (2.7) |
| Other | 3 (10.7) | 6 (20.7) | 5 (11.6) | 3 (8.1) |
| **Professional experience** | |  |  |  |
| mean (SD) years | 26.1 (10.2) | 25.31 (9.6) | 25.6 (10.0) | 25.6 (10.4) |
| **IAD-related activities** § | |  |  |  |
| Clinical trial | 8 (28.6) | 10 (34.5) | 16 (37.2) | 14 (37.8) |
| Quality improvement project | 12 (42.9) | 19 (65.5) | 24 (55.8) | 21 (56.8) |
| Education | 17 (60.7) | 22 (75.9) | 31 (72.1) | 29 (78.4) |
| Other | 8 (28.6) | 9 (31.0) | 10 (23.3) | 7 (18.9) |
| **IAD publication** |  |  |  |  |
| Yes | 11 (39.3) | 18 (62.1) | 24 (55.8) | 23 (62.2) |
| No | 17 (60.7) | 11 (37.9) | 19 (44.2) | 14 (37.8) |
| **Direct patient care** |  |  |  |  |
| Yes | 17 (60.7) | 19 (65.5) | 27 (62.8) | 24 (64.9) |
| No | 11 (39.3) | 10 (34.5) | 16 (37.2) | 13 (35.1) |
| IAD, incontinence-associated dermatitis; SD, standard deviation; Education, highest degree; IAD publication, if the panelist has published IAD-related articles. † 3-point scale [(1) not important enough to be considered in the COS for IAD, (2) important but not critical to be considered in the COS for IAD, and (3) critical, should be included in the COS for IAD]. ‡ 9-point scale [from ‘not important for inclusion’ to ‘critical, should be included in a COS for IAD’]. § Multiple answers possible. | | | | |